Nan Fung Trinity HK Ltd. Makes New $1.75 Million Investment in KalVista Pharmaceuticals, Inc. $KALV

Nan Fung Trinity HK Ltd. acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the second quarter, Holdings Channel.com reports. The firm acquired 154,522 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,747,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of New York Mellon Corp lifted its stake in KalVista Pharmaceuticals by 5.1% in the first quarter. Bank of New York Mellon Corp now owns 103,530 shares of the specialty pharmaceutical company’s stock valued at $1,195,000 after buying an additional 4,983 shares during the period. CWM LLC increased its stake in KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,549 shares in the last quarter. Earned Wealth Advisors LLC acquired a new position in shares of KalVista Pharmaceuticals during the first quarter valued at about $44,000. Vanguard Group Inc. increased its position in KalVista Pharmaceuticals by 1.9% in the 1st quarter. Vanguard Group Inc. now owns 2,298,598 shares of the specialty pharmaceutical company’s stock valued at $26,526,000 after buying an additional 43,355 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in KalVista Pharmaceuticals by 12.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 113,124 shares of the specialty pharmaceutical company’s stock valued at $1,305,000 after buying an additional 12,776 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have commented on KALV. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Citigroup restated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday. Citizens Jmp lowered their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, September 12th. Finally, JMP Securities increased their price objective on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. Ten analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $26.63.

KalVista Pharmaceuticals Stock Up 5.3%

KalVista Pharmaceuticals stock opened at $11.47 on Wednesday. The company’s 50 day moving average price is $12.27 and its two-hundred day moving average price is $12.81. The stock has a market cap of $579.50 million, a P/E ratio of -2.91 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.96) by $0.04. The firm had revenue of $13.69 million during the quarter, compared to analysts’ expectations of $6.03 million. On average, equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 2,336 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $13.42, for a total value of $31,349.12. Following the completion of the transaction, the insider owned 122,505 shares of the company’s stock, valued at $1,644,017.10. The trade was a 1.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 7,294 shares of KalVista Pharmaceuticals stock in a transaction on Monday, September 8th. The stock was sold at an average price of $15.84, for a total transaction of $115,536.96. Following the sale, the chief executive officer directly owned 395,189 shares of the company’s stock, valued at $6,259,793.76. This represents a 1.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,856 shares of company stock valued at $374,910 in the last three months. 4.30% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).